Fiduciary Alliance’s Faeth Therapeutics FTH Stock Holding History

Fiduciary Alliance’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3	Closed	-$75	–	753
2022 Q4	$75	Buy	+3	New	+$88	﹤0.01%	922

Other funds holding FTH

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fiduciary Alliance's FTH Position: Q1 2023 in Review

Fiduciary Alliance sold out of Faeth Therapeutics (FTH) in Q1 2023, closing a stake of 3 shares — an estimated $75 sold.

Fiduciary Alliance first reported a position in FTH in Q4 2022 and held it in 1 quarter. The position peaked at $75 in Q4 2022. 26 funds tracked by Wall St. Rank hold FTH as of Q1 2023.

Fiduciary Alliance reported no remaining Faeth Therapeutics position as of Q1 2023 after selling out during the quarter.
Fiduciary Alliance sold 3 Faeth Therapeutics shares in Q1 2023, an estimated $75.
Fiduciary Alliance first reported a position in Faeth Therapeutics in Q4 2022 and held it in 1 quarter.
Fiduciary Alliance's Faeth Therapeutics position peaked at $75 in Q4 2022.
26 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2023.

Based on Fiduciary Alliance's 13F filing for Q1 2023, filed 18 Apr 2023.